Your session is about to expire
← Back to Search
CAR T-cell Therapy
CAR T-Cell Therapy for Esophageal Cancer
Phase 1
Recruiting
Led By Geoffrey Ku, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Life expectancy of ≥4 months
Diagnosis of pathologically confirmed EG adenocarcinoma
Must not have
Receiving therapy for concurrent active malignancy
Active interstitial lung disease/pneumonitis or a history of interstitial lung disease/pneumonitis requiring treatment with systemic steroids
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
"This trial involves collecting white blood cells from participants, modifying them in a lab to become targeted CAR T cells, and then giving them back to the participants as a therapy. The whole process will take around
Who is the study for?
This trial is for individuals with certain types of cancer affecting the lining of organs, esophagus, or stomach. Participants must have T cells that can be collected and modified in a lab. Specific eligibility details are not provided but typically include factors like age, health status, and prior treatments.
What is being tested?
The study tests a new therapy where patients' own T cells are engineered to target cancer cells expressing mesothelin (MSLN). These modified T cells (M28z1XXPD1DNR CAR) are then given back to the patient to help fight the cancer.
What are the potential side effects?
While specific side effects aren't listed here, CAR T-cell therapies often cause immune system reactions such as fever, fatigue, headache, and can sometimes lead to more severe complications.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My doctor expects me to live for at least 4 more months.
Select...
I have been diagnosed with esophagogastric adenocarcinoma.
Select...
I am fully active or can carry out light work.
Select...
I am 18 years old or older.
Select...
I have received at least one treatment for my HER2 positive condition.
Select...
My cancer has worsened or I couldn't tolerate the treatment after at least one therapy.
Select...
My cancer has returned or spread to other parts of my body.
Select...
My tumor shows high MSLN levels.
Select...
My cancer is stage IV and has spread to the lining of my abdomen.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am currently being treated for another cancer.
Select...
I have or had lung inflammation that needed steroid treatment.
Select...
I do not have HIV or active hepatitis B or C infections.
Select...
I am taking 10 mg or more of prednisone daily or similar medications.
Select...
I have previously received CAR T cell therapy or another type of cellular therapy.
Select...
I have untreated brain metastases.
Select...
I have serious heart conditions or infections that are not under control.
Select...
I have had blood cancer treatment within the last 5 years.
Select...
I have had treatment targeting mesothelin before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Maximum Tolerated Dose of M28z1XXPD1DNR CAR T cells
Number of treatment-emergent adverse events
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Participants with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal CarcinomatosisExperimental Treatment1 Intervention
Participants will be diagnoses with Mesothelin-Positive Esophagogastric Adenocarcinoma with Peritoneal Carcinomatosis
Find a Location
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
599,820 Total Patients Enrolled
Geoffrey Ku, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
109 Total Patients Enrolled